Primecap Management Co. CA Sells 2,122 Shares of Sanofi (NASDAQ:SNY)

Primecap Management Co. CA decreased its position in shares of Sanofi (NASDAQ:SNY) by 0.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,117,328 shares of the company’s stock after selling 2,122 shares during the period. Primecap Management Co. CA’s holdings in Sanofi were worth $54,213,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. TCTC Holdings LLC grew its holdings in Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC grew its holdings in Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after buying an additional 221 shares in the last quarter. Wynn Capital LLC grew its holdings in Sanofi by 4.5% during the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after buying an additional 226 shares in the last quarter. Angeles Investment Advisors LLC grew its holdings in Sanofi by 2.1% during the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after buying an additional 244 shares in the last quarter. Finally, EP Wealth Advisors LLC grew its holdings in Sanofi by 5.3% during the 4th quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock valued at $250,000 after buying an additional 255 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Argus increased their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $57.50.

Sanofi Trading Down 0.7 %

SNY stock opened at $56.91 on Wednesday. The firm has a fifty day moving average price of $53.95 and a 200 day moving average price of $50.30. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $144.14 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 1.60 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same period last year, the firm posted $0.95 earnings per share. Sanofi’s revenue for the quarter was up 7.8% compared to the same quarter last year. Sell-side analysts anticipate that Sanofi will post 4.25 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.